Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer

Chinese Medical Journal

Volumn 119, Issue 16, 2006, Pages 1365-1373

  Wang, Hai Jun ^a   Yu, Chang Long ^a   Kishi, Hiroyuki ^b   Motoki, Kazumi ^b   Mao, Ze Bin ^c   Muraguchi, Atsushi ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b UNIVERSITY OF TOYAMA   (Japan)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Gene therapy; Interleukin 1; Osteoarthritis; Receptors; Tumor necrosis factor alpha

Indexed keywords

ADENOVIRUS VECTOR; EOSIN; GREEN FLUORESCENT PROTEIN; HEMATOXYLIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TOLONIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CELL CULTURE; CHONDROPROTECTION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMUR CONDYLE; GENE TRANSFER; GENETIC CODE; HISTOPATHOLOGY; IN VITRO STUDY; JOINT DESTRUCTION; KNEE LIGAMENT; KNEE OSTEOARTHRITIS; MENISCECTOMY; MICROSCOPY; NONHUMAN; PATELLA TENDON; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SYNOVIAL FLUID; SYNOVITIS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 33747735579     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200608020-00009     Document Type: Article

References (37)

1. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002; 14: 573-577.
2. Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC. Osteoarthritis gene therapy. Gene Ther 2004; 11: 379-389.
3. Evans CH, Ghivizzani SC, Kang R, Muzzonigro T, Wasko MC, Herndon JH. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42: 1-16.
4. Roessler BJ, Allen ED, Wilson JM, Hartman JW, Davidson BL. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993; 92: 1085-1092.
5. Ghivizzani SC, Lechman ER, Kang R, Tio C, Kolls J, Evans CH, et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A 1998; 95: 4613-4618.
6. Smith P, Shuler FD, Georgescu HI, Ghivizzani SC, Johnstone B, Niyibizi C, et al. Genetic enhancement of matrix synthesis by articular chondrocytes: comparison of different growth factor genes in the presence and absence of interleukin-1. Arthritis Rheum 2000; 43: 1156-1164.
7. Shuler FD, Georgescu HI, Niyibizi C, Studer RK, Mi Z, Johnstone B, et al. Increased matrix synthesis following adenoviral transfer of a transforming growth factor beta1 gene into articular chondrocytes. J Orthop Res 2000; 18: 585-592.
8. Baragi VM, Renkiewicz RR, Qiu L, Brammer D, Riley JM, Sigler RE, et al. Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo. Osteoarthritis Cartilage 1997; 5: 275-282.
9. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39: 237-246.
10. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547-549.
11. Towel CA, Hung HH, Bonassar LJ, Treadwell BV, Mangham DC. Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis. Osteoarthr Cartilage 1997; 5: 293-300.
12. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Gang C, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535-1544.
13. Van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 164-172.
14. Plows D, Probert L, Georgopoulos S, Kollias, G. The role of tumour necrosis factor (TNF) in arthritis: studies in transgenic mice. Rheumatol Eur 1995; Suppl 2: s51-s54.
15. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF-α, anti-IL-1α/ β, and IL-1Ra. Arthritis Rheum 1996; 39: 797-809.
16. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049-5055.
17. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012-1019.
18. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12-20.
19. Fernandes J, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, et al. In vivo transfer of interleukin-1 receptor antagonist gene in ostsoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999; 154: 1159-1169.
20. Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993; 92: 19-22.
21. Roux-Lombard P, Punzi L, Hasler F, Bas S, Todesco S, Gallati H, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-489.
22. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. Arthritis Rheum 1993; 36: 781-789.
23. Loetscher H, Steinmetz M, Lesslauer W. Tumor necrosis factor: receptors and inhibitors. Cancer Cells 1991; 3: 221-226.
24. Abe Y, Gatanaga M, Osuka Y, Burger RA, Granger GA, Gatanaga T. Role of 55- and 75-kDa tumor necrosis factor membrane receptors in the regulation of intercellular adhesion molecules-1 expression by HL-60 human promyelocytic leukemia cells in vitro. J Immunol 1993; 150: 5070-5079.
25. McIntyre K W, Stepan GJ, Kolinsky KD, Benjamin WR, Plocinski JM, Kaffka KL, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173: 931-939.
26. Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-1) β and IL-1 receptor antagonist (IL-1Ra) to human serum. High-affinity binding of IL-1Ra to soluble IL-1 receptor type I. Cytokine 1993; 5: 427-435.
27. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95: 2509-2514.
28. Hamilton JA, Slywka J. Stimulation of human synovial fibroblast plasminogen activator production by mononuclear cell supernatants. J Immunol 1981; 126: 851-855.
29. Yu CL, Qu MY, Tian DX, Ao YF, Zhao JY. Early articular cartilage changes in traumatic osteoarthritis. J Orthop Surg 1998; 6: 41-47.
30. Mi Z, Ghivizzani SC, Lechman ER, Jaffurs D, Glorioso JC, Evans CH, et al. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000; 43: 2563-2570.
31. Sommerlath KG, Gillquist J. The effect of anterior cruciate ligament resection and immediate or delayed implantation of a meniscus prosthesis on knee joint biomechanics and cartilage. An experimental study in rabbits. Clin Orthop Relat Res 1993; 289: 267-275.
32. Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res 2004; 22: 742-750.
33. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001; 60: 91-97.
34. Kim SH, Lechman ER, Kim S, Nash J, Oligino TJ, Robbins PD. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 2002; 6: 591-600.
35. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550.
36. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003; 48: 2173-2177.
37. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-1267.